RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.

About the Regulatory Profession

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Regulatory Code of Ethics

One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.

Regulatory Competency Framework

Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.

Regulatory Convergence

Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.

EMA Outlines GCP Inspection Plan for 2017

Posted 21 February 2017 | By Zachary Brennan

The European Medicines Agency (EMA) on Tuesday released its 2017 work plan for good clinical practice (GCP) inspections, which involves collaborating with the US Food and Drug Administration (FDA) to limit duplicative inspections.

Among other expectations for the coming year, the EMA’s GCP Inspectors Working Group will develop new and revised guidelines on the redaction of inspection reports to protect personal data and commercially confidential information, as well as collaborations with member states on other inspections, both of which align with the implementation of the new Clinical Trials Regulation.

Revisions on GCP guidelines for advanced therapy medicinal products and recommendations on the qualifications of inspectors verifying trial compliance with GCPs will be finalized in 2017.

EMA says the following objectives will drive its agenda in the coming year:

to define in advance the number of GCP inspections to be requested in 2017

to proactively select the focus areas on indications, populations, geographical locations of sites, recruitment rates, size of sponsors, size of CROs and tasks and other general trends

to ensure that diverse geographical regions are selected for inspection, including countries outside the EU from which a substantial amount of clinical trial data derives

to ensure that GCP inspector’s resources are allocated for the conduct of routine and “for cause” GCP inspections in the context of the centralized procedure

“In order to save resources, duplication of inspections should be avoided and increased inspection coverage will be ensured for MAA submitted to both, the Agency and the US FDA,” the work plan says.

Back in 2009, EMA and FDA launched its GCP initiative, which has expanded to include Japan’s Pharmaceuticals and Medical Devices Agency, which will continue in 2017 alongside the more recently established joint EMA-FDA generic drug application inspections initiative from 2013.

EMA will also look to assist other countries in the development of GCP inspection roles, including Albania, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Bosnia and Herzegovina and Kosovo.